Tirzepatide and sleep apnea: what the SURMOUNT-OSA trials found

Introduction

The FDA has approved tirzepatide (Zepbound) for adults with obesity and moderate-to-severe obstructive sleep apnea (OSA), alongside reduced-calorie eating and increased physical activity. 1 The SURMOUNT-OSA trials studied tirzepatide. They do not establish the same effect for semaglutide or every GLP‑1 medicine, and they do not show that people can stop positive airway pressure (PAP) treatment on their own.

What obstructive sleep apnea is

OSA occurs when the upper airway keeps narrowing or closing during sleep, disrupting breathing and sleep. A sleep study measures severity using the apnea-hypopnea index (AHI), the number of breathing pauses or shallow-breathing events per hour. A sleep clinician diagnoses OSA and recommends treatment based on your results and health.

What the SURMOUNT-OSA trials found

The two 52-week trials enrolled adults with obesity and moderate-to-severe OSA. One trial included people who could not or would not use PAP; the other included people using PAP. In the first trial, AHI fell by an average of 25.3 events per hour with tirzepatide and 5.3 with placebo. In the PAP trial, it fell by 29.3 events per hour with tirzepatide and 5.5 with placebo. Body weight decreased in both tirzepatide groups. 2

In the PAP trial, participants paused PAP for seven days before the week-52 sleep assessment. The trials did not evaluate when or whether people who used PAP should stop it. The trials cannot separate the effects of weight loss from other effects of tirzepatide. 2

Keep using prescribed PAP unless your sleep clinician changes the plan

Do not stop CPAP or another PAP treatment because you feel better or have lost weight. Contact your sleep clinician if your symptoms change or you lose a large amount of weight. A sleep study can show whether your OSA has improved and whether your clinician should adjust treatment.

Sleep symptoms during treatment

Nausea, vomiting, reflux, and other digestive effects can disrupt sleep for some people taking these medicines. Clinical trial evidence does not establish insomnia or vivid dreams as expected class-wide effects. Tell your prescriber about sleep problems that persist, worsen, or affect daily activities.

Track treatment alongside sleep

Shotsy can help you record doses and notes about sleep or symptoms. Bring those observations to your sleep clinician, who can interpret them alongside sleep-study results.

Conclusion

Tirzepatide reduced OSA severity in trials involving adults with obesity and moderate-to-severe OSA, and Zepbound has an FDA indication for this group. The results do not show that patients can stop PAP or that other GLP‑1 medicines have the same effect. Keep following your sleep clinician’s plan and ask before changing treatment.